Lombard Odier Asset Management USA Corp Lowers Stock Holdings in Cencora, Inc. $COR

Lombard Odier Asset Management USA Corp lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 48.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,112 shares of the company’s stock after selling 5,696 shares during the quarter. Lombard Odier Asset Management USA Corp’s holdings in Cencora were worth $2,064,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in COR. Norges Bank purchased a new position in shares of Cencora during the fourth quarter worth about $822,506,000. Marshall Wace LLP grew its holdings in shares of Cencora by 518.9% during the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Cencora by 528.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after buying an additional 1,241,186 shares during the last quarter. Viking Global Investors LP grew its holdings in shares of Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Cencora by 4.1% during the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after buying an additional 916,506 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $281.22 on Wednesday. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The stock’s 50 day moving average is $287.49 and its two-hundred day moving average is $326.05. The firm has a market capitalization of $54.71 billion, a PE ratio of 21.57, a P/E/G ratio of 1.52 and a beta of 0.59. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the previous year, the business posted $4.42 earnings per share. Cencora’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora announced that its board has initiated a share buyback plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 3.9% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on COR. Citigroup lowered their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Weiss Ratings lowered Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. UBS Group lifted their price objective on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Robert W. Baird lowered their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.